These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38848180)
1. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease. Taylor J; Jaros M; Chen C; Harrison J; Hilt D J Alzheimers Dis; 2024; 100(1):139-150. PubMed ID: 38848180 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
3. Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals. Villemagne VL; Doré V; Chong L; Kassiou M; Mulligan R; Feizpour A; Taylor J; Roesner M; Miller T; Rowe CC J Alzheimers Dis; 2024; 97(3):1463-1475. PubMed ID: 38250767 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
5. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255 [TBL] [Abstract][Full Text] [Related]
8. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies. Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271 [TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW; Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400 [TBL] [Abstract][Full Text] [Related]
10. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Levey AI; Qiu D; Zhao L; Hu WT; Duong DM; Higginbotham L; Dammer EB; Seyfried NT; Wingo TS; Hales CM; Gámez Tansey M; Goldstein DS; Abrol A; Calhoun VD; Goldstein FC; Hajjar I; Fagan AM; Galasko D; Edland SD; Hanfelt J; Lah JJ; Weinshenker D Brain; 2022 Jun; 145(6):1924-1938. PubMed ID: 34919634 [TBL] [Abstract][Full Text] [Related]
11. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL; Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401 [TBL] [Abstract][Full Text] [Related]
12. Comparing tau status determined via plasma pTau181, pTau231 and [ Tissot C; Therriault J; Kunach P; L Benedet A; Pascoal TA; Ashton NJ; Karikari TK; Servaes S; Lussier FZ; Chamoun M; Tudorascu DL; Stevenson J; Rahmouni N; Poltronetti NM; Pallen V; Bezgin G; Kang MS; Mathotaarachchi SS; Wang YT; Fernandez Arias J; Ferreira PCL; Ferrari-Souza JP; Vanmechelen E; Blennow K; Zetterberg H; Gauthier S; Rosa-Neto P EBioMedicine; 2022 Feb; 76():103837. PubMed ID: 35134647 [TBL] [Abstract][Full Text] [Related]
13. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P; Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms. Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812 [TBL] [Abstract][Full Text] [Related]